ifx biosimilar sim0006 antibody Search Results


ifx biosimilar  (Bio X Cell)
94
Bio X Cell ifx biosimilar
Drug tolerance profile of the total ADA quantitation in serum via the i-Tracker assays on IDS-iSYS. Drug and ADA-negative serum specimens were spiked with different levels of the ADAs and increasing drug concentrations. The levels represent increasing ADA baseline concentrations in serum (before addition of drug), where Level 1 corresponds to the lowest ADA concentration achieved. A log2 scale was used on the Y -axis. ( A ) Impact of increasing ADM concentrations on total anti-ADM Ab quantity. Level 1 through 8 are, respectively, 25, 36, 80, 218, 382, 698, 1035, and 1238 AU/mL. Different scales were used in between the line breaks of the X -axis to facilitate trend visualization across the drug concentrations used. ( B ) Impact of increasing <t>IFX</t> <t>concentrations</t> on total anti-IFX Ab quantitation. Level 1 through 7 correspond to 54, 79, 200, 415, 831, 1570, and 1973 AU/mL, respectively.
Ifx Biosimilar, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ifx+biosimilar+sim0006+antibody/pmc12523426-119-10-12?v=Bio+X+Cell
Average 94 stars, based on 1 article reviews
ifx biosimilar - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
bs-mab2  (Merck KGaA)
90
Merck KGaA bs-mab2
Drug tolerance profile of the total ADA quantitation in serum via the i-Tracker assays on IDS-iSYS. Drug and ADA-negative serum specimens were spiked with different levels of the ADAs and increasing drug concentrations. The levels represent increasing ADA baseline concentrations in serum (before addition of drug), where Level 1 corresponds to the lowest ADA concentration achieved. A log2 scale was used on the Y -axis. ( A ) Impact of increasing ADM concentrations on total anti-ADM Ab quantity. Level 1 through 8 are, respectively, 25, 36, 80, 218, 382, 698, 1035, and 1238 AU/mL. Different scales were used in between the line breaks of the X -axis to facilitate trend visualization across the drug concentrations used. ( B ) Impact of increasing <t>IFX</t> <t>concentrations</t> on total anti-IFX Ab quantitation. Level 1 through 7 correspond to 54, 79, 200, 415, 831, 1570, and 1973 AU/mL, respectively.
Bs Mab2, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ifx+biosimilar+sim0006+antibody/pm37833075-174-10-15?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
bs-mab2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
trastuzumab igg1  (Merck KGaA)
90
Merck KGaA trastuzumab igg1
Drug tolerance profile of the total ADA quantitation in serum via the i-Tracker assays on IDS-iSYS. Drug and ADA-negative serum specimens were spiked with different levels of the ADAs and increasing drug concentrations. The levels represent increasing ADA baseline concentrations in serum (before addition of drug), where Level 1 corresponds to the lowest ADA concentration achieved. A log2 scale was used on the Y -axis. ( A ) Impact of increasing ADM concentrations on total anti-ADM Ab quantity. Level 1 through 8 are, respectively, 25, 36, 80, 218, 382, 698, 1035, and 1238 AU/mL. Different scales were used in between the line breaks of the X -axis to facilitate trend visualization across the drug concentrations used. ( B ) Impact of increasing <t>IFX</t> <t>concentrations</t> on total anti-IFX Ab quantitation. Level 1 through 7 correspond to 54, 79, 200, 415, 831, 1570, and 1973 AU/mL, respectively.
Trastuzumab Igg1, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ifx+biosimilar+sim0006+antibody/pm37833075-174-17-21?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
trastuzumab igg1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
adm biosimilar  (Bio X Cell)
93
Bio X Cell adm biosimilar
Drug tolerance profile of the total ADA quantitation in serum via the i-Tracker assays on IDS-iSYS. Drug and ADA-negative serum specimens were spiked with different levels of the ADAs and increasing drug concentrations. The levels represent increasing ADA baseline concentrations in serum (before addition of drug), where Level 1 corresponds to the lowest ADA concentration achieved. A log2 scale was used on the Y -axis. ( A ) Impact of increasing ADM concentrations on total anti-ADM Ab quantity. Level 1 through 8 are, respectively, 25, 36, 80, 218, 382, 698, 1035, and 1238 AU/mL. Different scales were used in between the line breaks of the X -axis to facilitate trend visualization across the drug concentrations used. ( B ) Impact of increasing <t>IFX</t> <t>concentrations</t> on total anti-IFX Ab quantitation. Level 1 through 7 correspond to 54, 79, 200, 415, 831, 1570, and 1973 AU/mL, respectively.
Adm Biosimilar, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ifx+biosimilar+sim0006+antibody/pm41095666-78-1-3?v=Bio+X+Cell
Average 93 stars, based on 1 article reviews
adm biosimilar - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


Drug tolerance profile of the total ADA quantitation in serum via the i-Tracker assays on IDS-iSYS. Drug and ADA-negative serum specimens were spiked with different levels of the ADAs and increasing drug concentrations. The levels represent increasing ADA baseline concentrations in serum (before addition of drug), where Level 1 corresponds to the lowest ADA concentration achieved. A log2 scale was used on the Y -axis. ( A ) Impact of increasing ADM concentrations on total anti-ADM Ab quantity. Level 1 through 8 are, respectively, 25, 36, 80, 218, 382, 698, 1035, and 1238 AU/mL. Different scales were used in between the line breaks of the X -axis to facilitate trend visualization across the drug concentrations used. ( B ) Impact of increasing IFX concentrations on total anti-IFX Ab quantitation. Level 1 through 7 correspond to 54, 79, 200, 415, 831, 1570, and 1973 AU/mL, respectively.

Journal: Diagnostics

Article Title: Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients

doi: 10.3390/diagnostics15192447

Figure Lengend Snippet: Drug tolerance profile of the total ADA quantitation in serum via the i-Tracker assays on IDS-iSYS. Drug and ADA-negative serum specimens were spiked with different levels of the ADAs and increasing drug concentrations. The levels represent increasing ADA baseline concentrations in serum (before addition of drug), where Level 1 corresponds to the lowest ADA concentration achieved. A log2 scale was used on the Y -axis. ( A ) Impact of increasing ADM concentrations on total anti-ADM Ab quantity. Level 1 through 8 are, respectively, 25, 36, 80, 218, 382, 698, 1035, and 1238 AU/mL. Different scales were used in between the line breaks of the X -axis to facilitate trend visualization across the drug concentrations used. ( B ) Impact of increasing IFX concentrations on total anti-IFX Ab quantitation. Level 1 through 7 correspond to 54, 79, 200, 415, 831, 1570, and 1973 AU/mL, respectively.

Article Snippet: The ADM biosimilar (Bio X Cell Cat# SIM0001, RRID:AB_2894722) and IFX biosimilar (Bio X Cell Cat# SIM0006, RRID:AB_2894727) were acquired from Bio X Cell (Lebanon, NH, USA).

Techniques: Quantitation Assay, Concentration Assay